ACE2 and COVID-19: An ACE2-Fc decoy maintained and, in fact, gained potency against the Omicron BA.1 variant, which has 30 amino acid changes in the S protein, making it resistant to neutralization by almost all therapeutic monoclonal antibodies that have been developed to treat COVID-19 (2).